XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 14,593 $ 6,841
Short-term investments 0 252
Accounts receivable (net of allowance for doubtful accounts of $79 in 2024 and $88 in 2023) 11,381 10,349
Inventories (excludes inventories of $3,995 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6) 6,244 6,358
Other current assets 8,143 8,368
Total current assets 40,361 32,168
Investments 575 252
Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,072 in 2024 and $18,266 in 2023 23,446 23,051
Goodwill 21,697 21,197
Other Intangibles, Net 17,010 18,011
Other Assets 14,443 11,996
Total Assets 117,532 106,675
Current Liabilities    
Loans payable and current portion of long-term debt 3,149 1,372
Trade accounts payable 3,586 3,922
Accrued and other current liabilities 16,539 15,766
Income taxes payable 4,330 2,649
Dividends payable 1,982 1,985
Total current liabilities 29,586 25,694
Long-Term Debt 34,982 33,683
Deferred Income Taxes 864 871
Other Noncurrent Liabilities 7,540 8,792
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 1,788 1,788
Other paid-in capital 44,530 44,509
Retained earnings 61,384 53,895
Accumulated other comprehensive loss (5,371) (5,161)
Stockholders' equity before deduction for treasury stock 102,331 95,031
Less treasury stock, at cost: 1,045,073,377 shares in 2024 and 1,045,470,249 shares in 2023 57,829 57,450
Total Merck & Co., Inc. stockholders’ equity 44,502 37,581
Noncontrolling Interests 58 54
Total equity 44,560 37,635
Liabilities and Equity $ 117,532 $ 106,675